SOMERSET, N.J. – April 24, 2019 — Catalent (booth 1206), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its experts will participate in two conference sessions at the upcoming CPhI North America tradeshow at the Lakeside Center at McCormick Place, Chicago, on April 30 – May 2, 2019.
On Tuesday, April 30 at 9:45 a.m., Ronak Savla, Pharm.D., Ph.D., Scientific Affairs Manager, and co-chair of the Catalent Applied Drug Delivery Institute, has been invited to join the “Building a Better Drug: Strategies to Enhance Patient Drug Regimen” panel session. He will discuss roadblocks to patient adherence, and technologies and processes that can be employed to mitigate these problems including formulation methods, new dosage forms, excipients, and alternative delivery technologies.
On Wednesday, May 1 at 1:30 p.m., Mike Valazza, Vice President, Business Development, Oral Drug Delivery North America, will present “Advancements in Manufacturing Solutions”. His presentation will discuss current trends in pharmaceutical manufacturing, including the increase in the number of expedited programs, the need for integrated end-to-end solutions from Phase 1 to commercialization, and the adoption of technologies to assist in getting products to market faster.
Dr. Savla is responsible for the strategy of the scientific communications plan, management of external collaborations, scientific assessment of novel drug delivery technologies, oversight of internal technology development, and leadership of Catalent’s Scientific Excellence Initiative. He leads several initiatives within the company focusing on patient-focused drug design, including a collaboration with Rutgers University School of Pharmacy to investigate the challenges in pediatric dose form design. He received both his Doctor of Pharmacy degree and his doctorate from Rutgers University, New Brunswick, New Jersey.
Mr. Valazza has over 20 years’ experience in the pharmaceutical industry. Prior to joining Catalent in 2001, he held senior positions at several companies including International Processing Corporation, Glatt Air Techniques and Schering Pharmaceuticals. Mr. Valazza is a registered pharmacist, and a member of a variety of professional organizations including the American Pharmaceutical Association, the American Association of Pharmaceutical Scientists, and the Controlled Release Society. He received a bachelor’s degree in pharmacy from Rutgers University, New Brunswick, New Jersey.
At the show, Catalent executives will be available to discuss the recently announced acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, and will also share news of further network expansions. Catalent will be exhibiting and showcasing its multiple innovative technologies, and will host a bourbon tasting networking reception at Drumbar on Wednesday, May 1 at 7:30 p.m. For more information visit the Catalent booth 1206, or visit catalent.com.
To arrange a meeting with any of the attending Catalent executives at the event, contact Ed Dutton at NEPR - email@example.com.
+44 (0)7580 041073
+44 (0)161 728 5880
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With more than 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.